CART22-65s + huCART19

CART22-65s + huCART19 is a combination regimen of two autologous, humanized chimeric antigen receptor (CAR) T-cell therapies. CART22-65s is engineered to target the CD22 antigen, while huCART19 targets the CD19 antigen, both of which are frequently expressed on B-lineage malignancies. Each CAR construct utilizes a humanized single-chain variable fragment (scFv) for antigen recognition, linked to a 4-1BB (CD137) costimulatory domain and a CD3-zeta (TCRζ) signaling module. Developed by researchers at the Children's Hospital of Philadelphia and the University of Pennsylvania, this dual-targeting approach is being evaluated in Phase 1/2 clinical trials led by Dr. Stephan Grupp. The strategy is specifically designed for children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) or B-lineage lymphoblastic lymphoma, aiming to mitigate the risk of relapse caused by antigen escape (loss of CD19 or CD22 expression) following single-target CAR T-cell therapy.

Other names

Autologous humanized anti-CD22 CAR T cells co-administered with humanized anti-CD19 CAR T cellsAutologous humanized anti-CD22 CAR T cell therapyAutologous humanized anti-CD19 CAR T cell therapy